Compare DexCom, Inc. (DXCM) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Sibanye Stillwater Ltd — how do they compare? DexCom, Inc. trades at $77.1 (market cap $28.06B), while Sibanye Stillwater Ltd trades at $8.12 (market cap $5.93B). The key difference: DexCom, Inc. is far larger — about 4.7× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.64% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SBSW | |
|---|---|---|
Market Cap | $28.06B | $5.93B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $21.12 |
52-Week Low | $54.84 | $7.27 |
Enterprise Value | $27.03B | $7.56B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Sibanye Stillwater (SBSW) trades at $8.12, down 5.25% today, reflecting ongoing challenges despite a low P/E of 4.76 and P/S of 0.77. The stock shows bearish technical signals with key support at $8, while fundamentals reveal negative net income margins and ROE. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, yet earnings misses in recent quarters underscore persistent profitability issues.
The outlook is mixed: deep valuation discounts and analyst consensus targets near $14.25 suggest upside potential, but risks from volatile commodity prices, high debt, and inconsistent earnings warrant caution. Investors should weigh the turnaround narrative against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
